- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07943377
Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 Trial in Healthy Participants to Evaluate Single and Multiple Oral Dose Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Aligos Therapeutics
- Номер телефона: 800-466-6059
- Электронная почта: info@aligos.com
Места учебы
-
-
Wisconsin
-
Madison, Wisconsin, Соединенные Штаты, 53704
- Aligos Investigational Site
-
Контакт:
- Aligos Investigational Site
- Номер телефона: 800-466-6059
- Электронная почта: info@aligos.com
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria: Key Inclusion Criteria
- Parts A and B only: Male or female between 18 and 60 years of age
- Part C only: Males between 18 and 55 years of age.
- Body mass index between 18.0 kg/m2 and 32.0 kg/m2
- In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory assessments.
- Part C only: History of a minimum of 1 bowel movement per day.
Exclusion Criteria: Key Exclusion Criteria:
-
Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
-
History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
-
History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
-
Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute.
-
Positive hepatitis panel and/or positive human immunodeficiency virus test.
-
Parts A and B only: Any of the following at screening or check-in:
- QTcF >450 ms in males or >470 ms in females
- QRS duration >120 ms
- PR interval >210 ms
- findings which would make QTc measurements difficult or QTc data uninterpretable
-
Administration of any vaccine within 30 days prior to dosing.
-
Use or intend to use any prescription medications/products, other than hormone replacement therapy, within 14 days prior to dosing
-
Alcohol consumption of >21 units per week for males and >14 units per week for females, as applicable.
-
Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: ALG-000184
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of ALG-000184 |
|
Плацебо Компаратор: Placebo
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of Placebo |
|
Другой: [14C]ALG-000184
|
Single oral dose of [14C]ALG-000184 Single micodose of [13C7,15N1]ALG-001075 with combination of [14C]ALG-000184 |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Safety and Tolerability (Part A and B)
Временное ограничение: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-τ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including tmax t1/2 |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including ARAUC |
From enrollment to end of treatment at 10 days
|
|
Total radioactivity recovery (fet1-t2) in urine and feces (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Metabolic profiles of ALG-000184 (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Identification of ALG-000184 (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Bioavailability of ALG-001075 (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
Determine the absolute bioavailability of ALG-001075 following oral administration of [14C]ALG-000184 relative to IV administration of [13C7,15N1]ALG-001075 |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2 |
From enrollment to end of treatment at 10 days
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
QTc (Part A and B)
Временное ограничение: From enrollment to end of treatment at 10 days
|
Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants |
From enrollment to end of treatment at 10 days
|
|
Safety and Tolerability (Part C)
Временное ограничение: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
- ALG-000184-209
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .